Official Title
Convalescent Plasma in the Treatment of COVID 19
Brief Summary

The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.

Detailed Description

The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.

Enrolling by invitation
SARS-CoV-2
COVID
Coronavirus

Biological: Convalescent Plasma
treatment with 2 Units of convalescent plasma
COVID-19 patients treated with convalescent plasma

Eligibility Criteria

Inclusion Criteria:

- All genders

- Age > 18 yrs and < 90 yrs

- Must have laboratory confirmed COVID-19

- Must provide informed consent

- Must have severe or immediately life-threatening COVID-19,

Severe disease is defined as:

- dyspnea,

- respiratory frequency ≥ 30/min,

- blood oxygen saturation ≤ 93%,

- partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300

- lung infiltrates > 50% within 24 to 48 hours

Life-threatening disease is defined as:

- respiratory failure,

- septic shock

- multiple organ dysfunction or failure

Exclusion Criteria:

- No gender exclusion

- Age < 18 yrs and > 90 yrs

- COVID-19 negative

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 90 Years
Countries
United States
Locations

Trinity Health Of New England
Hartford, Connecticut, 06105

Latha Dulipsingh, MD
Principal Investigator
Saint Francis Hospital and Medical Centerr/Trinity Health Of New England

Saint Francis Care
NCT Number
Keywords
SARS-CoV-1
Covid
Coronavirus
Convalescent plasma
plasma
MeSH Terms
Coronavirus Infections